Press releases

Filter
131 found

Kozenis (tafenoquine) approved by the Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria

21 Sep 2018

Severe malaria case fatality reduced by 96% in pilot project in Zambia led by Transaid, MMV and partners

28 Aug 2018

US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria

20 Jul 2018

US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of P. vivax malaria

12 Jul 2018

WHO provides first-ever approval for rectal artesunate product for severe malaria

27 Feb 2018

GSK submits US regulatory application for single-dose tafenoquine for Plasmodium vivax malaria

28 Nov 2017

KAF156 enters phase IIb combination studies

21 Aug 2017

Cipla launches quality-assured Rectal Artesunate Suppositories for severe malaria in young children

25 Jul 2017

Three MMV-supported antimalarials listed as essential medicines

16 Jun 2017

MMV and GSK announce positive headline phase III results showing single-dose tafenoquine reduces risk of relapse in patients with Plasmodium vivax malaria

12 Jun 2017

MMV and Zydus join forces to develop new antimalarial

27 Sep 2016

UCT-H3D, MMV and international partners identify second potent antimalarial candidate

27 Jul 2016

MMV and Novartis expand partnership

15 Jun 2016

MMV joins Swiss Malaria Group in Bern to commemorate World Malaria Day

25 Apr 2016

Netherlands-based consortium teams up with MMV in world-leading malaria translational research programme

25 Apr 2016

Pyramax® granules (pyronaridine-artesunate) for children added to WHO list of prequalified medicines

20 Apr 2016
children

MMV announces collaborative agreement with S Kant HEALTHCARE Ltd

10 Mar 2016

Pyramax® Granules becomes first paediatric antimalarial to receive EMA Article 58 positive scientific opinion

20 Nov 2015

MMV provides QIMR Berghofer AU$10 M for malaria drug development

08 Nov 2015

GHIT invests $10.7 million in malaria, TB, leishmaniasis and dengue research

05 Nov 2015
Prof. Djimde and students at WANECAM Molecular Biology Workshop MRC Gambia

New study details safety and efficacy of re-treatment with Pyramax®

23 Oct 2015

New compound has the potential to treat malaria patients in a single dose

17 Jun 2015

GHIT, Takeda and MMV progress first-in-class antimalarial DSM265 to patient trials in Peruvian Amazon

05 Jun 2015

Merck Serono and MMV sign agreement to develop potential antimalarial therapy

01 Apr 2015

Japanese global health fund announces new investment in promising compounds for antimalarial drug discovery

05 Feb 2015

Independent Safety Monitoring Board assessment enables recruitment of 2-5 year olds into OZ439/PQP Phase IIb trial

20 Jan 2015

MMV announces collaborations with Cipla and Strides

27 Nov 2014

GSK and MMV announce start of Phase III programme of tafenoquine

28 Apr 2014

Potential new antimalarial drug identified at the University of Dundee

06 Feb 2014

Breakthrough Therapy designation for potential new anti-relapse medicine for malaria

20 Dec 2013

Campaign launched to help eliminate malaria deaths

23 Sep 2013

Australian first to advance malaria medicines

19 Aug 2013

Japan launches bold effort to fight neglected diseases

31 May 2013

Winners of malaria photo contest announced

22 Apr 2013

Japan’s First PPP to Spearhead Innovation in Global Health

08 Apr 2013

Open access initiative reveals drug hits for deadly neglected tropical diseases

13 Nov 2012

African antimalarial research bears first fruit

28 Aug 2012

MMV assesses risk of resistance

22 Aug 2012

Delivery of child-friendly antimalarial hits the 100 million mark

22 Feb 2012

One step closer to blocking the transmission of malaria

21 Feb 2012

Pyramax® receives positive opinion from the EMA

20 Feb 2012

MMV and SCYNEXIS offer 400 active compounds for neglected disease drug research at no cost

19 Dec 2011

New generation of lifesaving medicines and vaccines for the world’s poor now at risk

08 Dec 2011

Marketing authorization for Eurartesim® announced at media roundtable

30 Nov 2011

New dual-acting antimalarial compounds discovered

17 Nov 2011

Partnership reaches important milestone

14 Nov 2011

Patient screening underway for Pyramax® sub-study in Sotuba, Mali

09 Nov 2011

Antimalarial drug discovery urgently needs prioritised 5-year plan to avoid missing opportunities

11 Oct 2011

Molecule moves through preclinical development in record time

02 Sep 2011

Artemisinin’s key impurities identified and made available as reference standards

20 Jun 2011

MMV supports new technique to measure quality of artemisinin

06 Jun 2011

MMV participates in Asia Pacific efforts to eliminate malaria

25 May 2011

Sanofi-aventis and MMV join forces to develop innovative malaria drugs

05 May 2011

"SMS for Life" rolled-out nationwide in the United Republic of Tanzania

18 Apr 2011

Anacor Pharmaceuticals and MMV sign agreement to pursue promising compound for malaria

18 Mar 2011

Jomaa Pharma and MMV to co-develop novel malaria treatment based on fosmidomycin

15 Feb 2011

Single-dose cure for malaria edges closer to the clinic

08 Feb 2011

International status granted to three not-for-profit organizations in Switzerland

09 Dec 2010

MMV, Novartis and partners discover novel antimalarial drug candidate

03 Sep 2010

MMV becomes first PDP to make its IP freely available for neglected diseases research

16 Aug 2010

Pages